{
  "version": "3.0",
  "updated": "2026-02-04",
  "description": "181 biotech companies - 48 with curated IR data from presentations",
  "stats": {
    "total": 181,
    "with_data": 5,
    "by_priority": {
      "high": 17,
      "medium": 29,
      "low": 135
    }
  },
  "companies": [
    {
      "ticker": "ARGX",
      "name": "argenx SE",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "high",
      "ir_priority": "HIGH",
      "has_data": true,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "ARWR",
      "name": "Arrowhead Pharmaceuticals",
      "development_stage": "platform",
      "modality": "rna_therapeutics",
      "therapeutic_area": "mixed",
      "priority": "high",
      "ir_priority": "HIGH",
      "has_data": true,
      "market_cap_mm": "$4.2B",
      "ir_url": "",
      "notes": "RNAi platform with extra-hepatic delivery (TRiM). View thesis: /companies/ARWR/thesis"
    },
    {
      "ticker": "ASND",
      "name": "Ascendis Pharma",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "high",
      "ir_priority": "HIGH",
      "has_data": true,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "CDTX",
      "name": "Cidara Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "high",
      "ir_priority": "MED-HIGH",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "CNTA",
      "name": "Centessa Pharmaceuticals",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "high",
      "ir_priority": "HIGH",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "ELVN",
      "name": "Enliven Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "high",
      "ir_priority": "MED-HIGH",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "EWTX",
      "name": "Edgewise Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "high",
      "ir_priority": "HIGH",
      "has_data": true,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "GPCR",
      "name": "Structure Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "high",
      "ir_priority": "MED-HIGH",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "KYMR",
      "name": "Kymera Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "high",
      "ir_priority": "HIGH",
      "has_data": true,
      "market_cap_mm": "$3.5B",
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "MLYS",
      "name": "Mineralys Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "high",
      "ir_priority": "MED-HIGH",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "NAMS",
      "name": "NewAmsterdam Pharma",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "high",
      "ir_priority": "MED-HIGH",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "NUVL",
      "name": "Nuvalent",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "high",
      "ir_priority": "HIGH",
      "has_data": true,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "OCUL",
      "name": "Ocular Therapeutix",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "high",
      "ir_priority": "MED-HIGH",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "ORKA",
      "name": "Oruka Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "high",
      "ir_priority": "MED-HIGH",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "SION",
      "name": "Sionna Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "high",
      "ir_priority": "MED-HIGH",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "SLNO",
      "name": "Soleno Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "high",
      "ir_priority": "HIGH",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "TRML",
      "name": "Tourmaline Bio",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "high",
      "ir_priority": "MED-HIGH",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "ACRV",
      "name": "Acrivon Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MED-LOW",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "ALNY",
      "name": "Alnylam Pharmaceuticals",
      "development_stage": "platform",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MEDIUM",
      "has_data": false,
      "market_cap_mm": "$28.5B",
      "ir_url": "",
      "notes": "RNA therapeutics leader"
    },
    {
      "ticker": "ARTV",
      "name": "Artiva Biotherapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MED-LOW",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "BCAX",
      "name": "Bicara Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MEDIUM",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "CLYM",
      "name": "Climb Bio",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MED-LOW",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "CTMX",
      "name": "CytomX Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MED-LOW",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "DNTH",
      "name": "Dianthus Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MEDIUM",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "ELDN",
      "name": "Eledon Pharmaceuticals",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MED-LOW",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "FDMT",
      "name": "4D Molecular Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MED-LOW",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "GHRS",
      "name": "GH Research",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MEDIUM",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "GKOS",
      "name": "Glaukos",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MED-LOW",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "HOWL",
      "name": "Werewolf Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MED-LOW",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "INSP",
      "name": "Inspire Medical Systems",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MED-LOW",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "IRON",
      "name": "Disc Medicine",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MEDIUM",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "JBIO",
      "name": "Jade Biosciences",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MED-LOW",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "LENZ",
      "name": "Lenz Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MEDIUM",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "LRMR",
      "name": "Larimar Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MED-LOW",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "MTSR",
      "name": "Metsera",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MED-LOW",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "NKTX",
      "name": "Nkarta",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MED-LOW",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "PEPG",
      "name": "PepGen",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MED-LOW",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "PHVS",
      "name": "Pharvaris",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MED-LOW",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "SEPN",
      "name": "Septerna",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MEDIUM",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "SLDB",
      "name": "Solid Biosciences",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MED-LOW",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "SPRY",
      "name": "ARS Pharmaceuticals",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MEDIUM",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "SRZN",
      "name": "Surrozen",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MED-LOW",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "TNGX",
      "name": "Tango Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MED-LOW",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "TSHA",
      "name": "Taysha Gene Therapies",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MEDIUM",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "TYRA",
      "name": "Tyra Biosciences",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MEDIUM",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "WGS",
      "name": "GeneDx",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "medium",
      "ir_priority": "MED-LOW",
      "has_data": false,
      "market_cap_mm": 0,
      "ir_url": "",
      "notes": ""
    },
    {
      "ticker": "ABBV",
      "name": "AbbVie",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$300B+",
      "ir_url": "",
      "notes": "I&I, Oncology, Neuro. Key products: Humira, Skyrizi, Rinvoq."
    },
    {
      "ticker": "ABUS",
      "name": "Arbutus Biopharma",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.3B",
      "ir_url": "",
      "notes": "Infectious - HBV cure."
    },
    {
      "ticker": "ACAD",
      "name": "Acadia Pharmaceuticals",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$4.5B",
      "ir_url": "",
      "notes": "Neuropsychiatry. Key products: Nuplazid, Daybue."
    },
    {
      "ticker": "ACLX",
      "name": "Arcellx",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$3.5B",
      "ir_url": "",
      "notes": "Oncology - CAR-T."
    },
    {
      "ticker": "ADMA",
      "name": "ADMA Biologics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$3.0B",
      "ir_url": "",
      "notes": "I&I (Immunoglobulins). Key product: ASCENIV."
    },
    {
      "ticker": "AGIO",
      "name": "Agios Pharmaceuticals",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$3.0B",
      "ir_url": "",
      "notes": "Rare - Hematology. Key product: Pyrukynd."
    },
    {
      "ticker": "AKBA",
      "name": "Akebia Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.2B",
      "ir_url": "",
      "notes": "Nephrology - anemia."
    },
    {
      "ticker": "AKRO",
      "name": "Akero Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$2.5B",
      "ir_url": "",
      "notes": "Metabolic - MASH. Lead: efruxifermin."
    },
    {
      "ticker": "ALEC",
      "name": "Alector",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.8B",
      "ir_url": "",
      "notes": "Neurodegeneration - immuno-neurology."
    },
    {
      "ticker": "ALKS",
      "name": "Alkermes",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$5.0B",
      "ir_url": "",
      "notes": "Neuropsychiatry. Key products: Vivitrol, Aristada."
    },
    {
      "ticker": "ALT",
      "name": "Altimmune",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.8B",
      "ir_url": "",
      "notes": "Metabolic - obesity."
    },
    {
      "ticker": "AMGN",
      "name": "Amgen",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$150B+",
      "ir_url": "",
      "notes": "Oncology, I&I, Bone. Key products: Repatha, Prolia, Lumakras."
    },
    {
      "ticker": "ANAB",
      "name": "AnaptysBio",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$2.5B",
      "ir_url": "",
      "notes": "I&I - Dermatology. Lead: rosnilimab."
    },
    {
      "ticker": "ANNX",
      "name": "Annexon Biosciences",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.5B",
      "ir_url": "",
      "notes": "Neuro - complement C1q."
    },
    {
      "ticker": "APGE",
      "name": "Apogee Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$2.5B",
      "ir_url": "",
      "notes": "I&I - next-gen biologics."
    },
    {
      "ticker": "APLS",
      "name": "Apellis Pharmaceuticals",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$5.0B",
      "ir_url": "",
      "notes": "Ophthalmology. Key product: Syfovre."
    },
    {
      "ticker": "ARDX",
      "name": "Ardelyx",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$1.5B",
      "ir_url": "",
      "notes": "Nephrology, GI. Key products: Ibsrela, Xphozah."
    },
    {
      "ticker": "ARVN",
      "name": "Arvinas",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$2.0B",
      "ir_url": "",
      "notes": "Oncology - protein degraders."
    },
    {
      "ticker": "AXSM",
      "name": "Axsome Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$4.0B",
      "ir_url": "",
      "notes": "Neuropsychiatry. Key products: Auvelity, Sunosi."
    },
    {
      "ticker": "BCRX",
      "name": "BioCryst Pharmaceuticals",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$3.5B",
      "ir_url": "",
      "notes": "Rare Disease. Key product: Orladeyo."
    },
    {
      "ticker": "BEAM",
      "name": "Beam Therapeutics",
      "development_stage": "platform",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$3.1B",
      "ir_url": "",
      "notes": "Rare Disease (Gene Editing). Lead: BEAM-101 (Ph1/2)."
    },
    {
      "ticker": "BHVN",
      "name": "Biohaven",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$3.0B",
      "ir_url": "",
      "notes": "Neuropsychiatry. Lead: taldefgrobep."
    },
    {
      "ticker": "BIIB",
      "name": "Biogen",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$25B",
      "ir_url": "",
      "notes": "Neuropsychiatry. Key products: Leqembi, Spinraza, Tysabri."
    },
    {
      "ticker": "BLUE",
      "name": "bluebird bio",
      "development_stage": "platform",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.3B",
      "ir_url": "",
      "notes": "Gene Therapy. Key products: Zynteglo, Lyfgenia."
    },
    {
      "ticker": "BMRN",
      "name": "BioMarin Pharmaceutical",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$12B",
      "ir_url": "",
      "notes": "Rare Disease. Key products: Voxzogo, Palynziq, Roctavian."
    },
    {
      "ticker": "BNTX",
      "name": "BioNTech",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$25B",
      "ir_url": "",
      "notes": "mRNA vaccines and oncology."
    },
    {
      "ticker": "CALT",
      "name": "Calliditas Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$1.5B",
      "ir_url": "",
      "notes": "Rare - IgAN. Key product: Tarpeyo."
    },
    {
      "ticker": "CBAY",
      "name": "CymaBay Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$2.5B",
      "ir_url": "",
      "notes": "Metabolic - PBC. Key product: seladelpar."
    },
    {
      "ticker": "CDNA",
      "name": "CareDx",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.8B",
      "ir_url": "",
      "notes": "Dx - Transplant. Key product: AlloSure."
    },
    {
      "ticker": "COGT",
      "name": "Cogent Biosciences",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$2.0B",
      "ir_url": "",
      "notes": "Oncology - KIT inhibitor."
    },
    {
      "ticker": "CPRX",
      "name": "Catalyst Pharmaceuticals",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$2.5B",
      "ir_url": "",
      "notes": "Neuropsychiatry. Key product: Firdapse."
    },
    {
      "ticker": "CRNX",
      "name": "Crinetics Pharmaceuticals",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$4.0B",
      "ir_url": "",
      "notes": "Endocrinology. Lead: paltusotine."
    },
    {
      "ticker": "CRSP",
      "name": "CRISPR Therapeutics",
      "development_stage": "platform",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$3.5B",
      "ir_url": "",
      "notes": "Rare Disease (Gene Editing). Key product: Casgevy."
    },
    {
      "ticker": "CYTK",
      "name": "Cytokinetics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$5.5B",
      "ir_url": "",
      "notes": "Cardiovascular. Key product: Myqorzo."
    },
    {
      "ticker": "DAWN",
      "name": "Day One Biopharmaceuticals",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$1.5B",
      "ir_url": "",
      "notes": "Oncology - pediatric. Key product: Ojemda."
    },
    {
      "ticker": "DNLI",
      "name": "Denali Therapeutics",
      "development_stage": "commercial_stage",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$4.0B",
      "ir_url": "",
      "notes": "Neurodegeneration. Lead: DNL310."
    },
    {
      "ticker": "DVAX",
      "name": "Dynavax Technologies",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$1.5B",
      "ir_url": "",
      "notes": "Vaccines. Key product: Heplisav-B."
    },
    {
      "ticker": "DYN",
      "name": "Dyne Therapeutics",
      "development_stage": "platform",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$2.0B",
      "ir_url": "",
      "notes": "Neuromuscular - AOC platform."
    },
    {
      "ticker": "EDIT",
      "name": "Editas Medicine",
      "development_stage": "platform",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.3B",
      "ir_url": "",
      "notes": "Gene Editing - in vivo."
    },
    {
      "ticker": "ETNB",
      "name": "89bio",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$1.5B",
      "ir_url": "",
      "notes": "Metabolic - MASH. Lead: pegozafermin."
    },
    {
      "ticker": "EXAS",
      "name": "Exact Sciences",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$19.4B",
      "ir_url": "",
      "notes": "Dx - Oncology. Key products: Cologuard, Oncotype DX."
    },
    {
      "ticker": "EXEL",
      "name": "Exelixis",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$8B",
      "ir_url": "",
      "notes": "Oncology. Key product: Cabometyx."
    },
    {
      "ticker": "FATE",
      "name": "Fate Therapeutics",
      "development_stage": "platform",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.3B",
      "ir_url": "",
      "notes": "iPSC-derived cell therapy."
    },
    {
      "ticker": "FGEN",
      "name": "FibroGen",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.2B",
      "ir_url": "",
      "notes": "Fibrosis, Anemia. Lead: pamrevlumab."
    },
    {
      "ticker": "FOLD",
      "name": "Amicus Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$3.2B",
      "ir_url": "",
      "notes": "Rare - Lysosomal. Key products: Galafold, Pombiliti."
    },
    {
      "ticker": "FULC",
      "name": "Fulcrum Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.5B",
      "ir_url": "",
      "notes": "Rare Disease. Lead: losmapimod."
    },
    {
      "ticker": "GERN",
      "name": "Geron Corporation",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$3.0B",
      "ir_url": "",
      "notes": "Oncology - telomerase. Key product: Rytelo."
    },
    {
      "ticker": "GH",
      "name": "Guardant Health",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$4.0B",
      "ir_url": "",
      "notes": "Dx - Oncology. Key products: Guardant360, Shield."
    },
    {
      "ticker": "GILD",
      "name": "Gilead Sciences",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$95B+",
      "ir_url": "",
      "notes": "HIV, Oncology, Liver. Key products: Biktarvy, Trodelvy, Livdelzi."
    },
    {
      "ticker": "GRAL",
      "name": "Grail",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$2.0B",
      "ir_url": "",
      "notes": "Dx - Oncology. Key product: Galleri."
    },
    {
      "ticker": "HALO",
      "name": "Halozyme Therapeutics",
      "development_stage": "platform",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$7.2B",
      "ir_url": "",
      "notes": "Drug Delivery. ENHANZE royalties."
    },
    {
      "ticker": "HIMS",
      "name": "Hims & Hers Health",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$5.0B",
      "ir_url": "",
      "notes": "Telehealth - consumer health."
    },
    {
      "ticker": "IDYA",
      "name": "IDEAYA Biosciences",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$2.5B",
      "ir_url": "",
      "notes": "Oncology - synthetic lethality."
    },
    {
      "ticker": "IGMS",
      "name": "IGM Biosciences",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.5B",
      "ir_url": "",
      "notes": "Oncology - IgM antibodies."
    },
    {
      "ticker": "IMGN",
      "name": "ImmunoGen",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0B",
      "ir_url": "",
      "notes": "Oncology - ADC. Key product: Elahere."
    },
    {
      "ticker": "IMTX",
      "name": "Immatics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$1.5B",
      "ir_url": "",
      "notes": "Oncology - TCR-T."
    },
    {
      "ticker": "IMVT",
      "name": "Immunovant",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$5.0B",
      "ir_url": "",
      "notes": "I&I (FcRn). Lead: batoclimab (Ph3)."
    },
    {
      "ticker": "INCY",
      "name": "Incyte",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$14B",
      "ir_url": "",
      "notes": "Oncology, I&I. Key products: Jakafi, Opzelura."
    },
    {
      "ticker": "INSM",
      "name": "Insmed",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$34.7B",
      "ir_url": "",
      "notes": "Rare - Pulmonary. Key products: Arikayce, Brinsupri."
    },
    {
      "ticker": "IONS",
      "name": "Ionis Pharmaceuticals",
      "development_stage": "platform",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$7.8B",
      "ir_url": "",
      "notes": "Neuro, Cardio, Rare. Key products: SPINRAZA, WAINUA."
    },
    {
      "ticker": "IOVA",
      "name": "Iovance Biotherapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$3.0B",
      "ir_url": "",
      "notes": "Oncology - TIL therapy. Key product: Amtagvi."
    },
    {
      "ticker": "IRWD",
      "name": "Ironwood Pharmaceuticals",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$1.0B",
      "ir_url": "",
      "notes": "GI. Key product: Linzess."
    },
    {
      "ticker": "ITCI",
      "name": "Intra-Cellular Therapies",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$8.0B",
      "ir_url": "",
      "notes": "Neuropsychiatry. Key product: Caplyta."
    },
    {
      "ticker": "JANX",
      "name": "Janux Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$2.0B",
      "ir_url": "",
      "notes": "Oncology - T cell engagers. Lead: JANX007."
    },
    {
      "ticker": "KALA",
      "name": "Kala Pharmaceuticals",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.1B",
      "ir_url": "",
      "notes": "Ophthalmology. Key product: Eysuvis."
    },
    {
      "ticker": "KALV",
      "name": "KalVista Pharmaceuticals",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$2.5B",
      "ir_url": "",
      "notes": "Rare - HAE. Lead: sebetralstat."
    },
    {
      "ticker": "KROS",
      "name": "Keros Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$1.5B",
      "ir_url": "",
      "notes": "Hematology. Lead: elritercept."
    },
    {
      "ticker": "KRYS",
      "name": "Krystal Biotech",
      "development_stage": "platform",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$7B",
      "ir_url": "",
      "notes": "Rare - Dermatology. Key product: Vyjuvek."
    },
    {
      "ticker": "LEGN",
      "name": "Legend Biotech",
      "development_stage": "commercial_stage",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$10B",
      "ir_url": "",
      "notes": "Oncology - CAR-T. Key product: Carvykti."
    },
    {
      "ticker": "LNTH",
      "name": "Lantheus Holdings",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$6.0B",
      "ir_url": "",
      "notes": "Diagnostics - radiopharmaceuticals."
    },
    {
      "ticker": "LQDA",
      "name": "Liquidia Technologies",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$1.5B",
      "ir_url": "",
      "notes": "Rare - PAH. Key product: Yutrepia."
    },
    {
      "ticker": "LYEL",
      "name": "Lyell Immunopharma",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.5B",
      "ir_url": "",
      "notes": "Oncology - next-gen T cell."
    },
    {
      "ticker": "MDGL",
      "name": "Madrigal Pharmaceuticals",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$6.8B",
      "ir_url": "",
      "notes": "Metabolic - MASH. Key product: Rezdiffra."
    },
    {
      "ticker": "MDXH",
      "name": "MDxHealth",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.3B",
      "ir_url": "",
      "notes": "Dx - Urology."
    },
    {
      "ticker": "MIRM",
      "name": "Mirum Pharmaceuticals",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$4.5B",
      "ir_url": "",
      "notes": "Rare - Liver. Key product: Livmarli."
    },
    {
      "ticker": "MNKD",
      "name": "MannKind",
      "development_stage": "commercial_stage",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$1.0B",
      "ir_url": "",
      "notes": "Diabetes, Pulmonary. Key products: Afrezza, Tyvaso DPI."
    },
    {
      "ticker": "MRNA",
      "name": "Moderna",
      "development_stage": "platform",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$15B",
      "ir_url": "",
      "notes": "Vaccines, Oncology, Rare. COVID/RSV vaccines platform."
    },
    {
      "ticker": "MRUS",
      "name": "Merus",
      "development_stage": "commercial_stage",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$8.0B",
      "ir_url": "",
      "notes": "Oncology - bispecific antibodies. Lead: zenocutuzumab."
    },
    {
      "ticker": "MRVI",
      "name": "Maravai LifeSciences",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$1.5B",
      "ir_url": "",
      "notes": "Tools - nucleic acid production."
    },
    {
      "ticker": "MYGN",
      "name": "Myriad Genetics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$2.0B",
      "ir_url": "",
      "notes": "Dx - Oncology, Women's Health."
    },
    {
      "ticker": "NBIX",
      "name": "Neurocrine Biosciences",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$14B",
      "ir_url": "",
      "notes": "Neuropsychiatry. Key product: Ingrezza."
    },
    {
      "ticker": "NTLA",
      "name": "Intellia Therapeutics",
      "development_stage": "platform",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$2.8B",
      "ir_url": "",
      "notes": "Rare Disease (Gene Editing). Lead: NTLA-2001 (Ph3)."
    },
    {
      "ticker": "NTRA",
      "name": "Natera",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$33B",
      "ir_url": "",
      "notes": "Dx - Oncology, Prenatal. Key products: Signatera, Panorama."
    },
    {
      "ticker": "NUVB",
      "name": "Nuvation Bio",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.8B",
      "ir_url": "",
      "notes": "Oncology - targeted therapies."
    },
    {
      "ticker": "NVAX",
      "name": "Novavax",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$1.2B",
      "ir_url": "",
      "notes": "Vaccines. COVID vaccine."
    },
    {
      "ticker": "OGN",
      "name": "Organon",
      "development_stage": "commercial_stage",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$5.0B",
      "ir_url": "",
      "notes": "Women's Health, Biosimilars."
    },
    {
      "ticker": "OMER",
      "name": "Omeros Corporation",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.3B",
      "ir_url": "",
      "notes": "Complement. Lead: narsoplimab."
    },
    {
      "ticker": "PCRX",
      "name": "Pacira BioSciences",
      "development_stage": "commercial_stage",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$1.5B",
      "ir_url": "",
      "notes": "Pain management. Key product: Exparel."
    },
    {
      "ticker": "PCVX",
      "name": "Vaxcyte",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$12B",
      "ir_url": "",
      "notes": "Vaccines - Pneumococcal. Lead: VAX-31."
    },
    {
      "ticker": "PRAX",
      "name": "Praxis Precision Medicines",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.5B",
      "ir_url": "",
      "notes": "Neuropsychiatry - Genetic CNS."
    },
    {
      "ticker": "PRME",
      "name": "Prime Medicine",
      "development_stage": "platform",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.8B",
      "ir_url": "",
      "notes": "Prime Editing platform. Lead: PM359 (Ph1)."
    },
    {
      "ticker": "PTCT",
      "name": "PTC Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$2.5B",
      "ir_url": "",
      "notes": "Rare Disease. Key products: Translarna, Evrysdi royalties."
    },
    {
      "ticker": "PTGX",
      "name": "Protagonist Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$3.5B",
      "ir_url": "",
      "notes": "GI, Hematology. Lead: rusfertide."
    },
    {
      "ticker": "QURE",
      "name": "uniQure",
      "development_stage": "platform",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.5B",
      "ir_url": "",
      "notes": "Gene Therapy. Key product: Hemgenix."
    },
    {
      "ticker": "RARE",
      "name": "Ultragenyx Pharmaceutical",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$4.5B",
      "ir_url": "",
      "notes": "Rare Disease. Key products: Crysvita, Evkeeza."
    },
    {
      "ticker": "RCKT",
      "name": "Rocket Pharmaceuticals",
      "development_stage": "commercial_stage",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$2.0B",
      "ir_url": "",
      "notes": "Gene Therapy. Key product: Kresladi."
    },
    {
      "ticker": "RCUS",
      "name": "Arcus Biosciences",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$2.5B",
      "ir_url": "",
      "notes": "Oncology - immuno-oncology."
    },
    {
      "ticker": "REGN",
      "name": "Regeneron Pharmaceuticals",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "ir_priority": "LOW",
      "has_data": false,
      "market_cap_mm": "$90B+",
      "ir_url": "",
      "notes": "Reference company for Dupixent comparisons"
    },
    {
      "ticker": "REPL",
      "name": "Replimune Group",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.8B",
      "ir_url": "",
      "notes": "Oncology - oncolytic immunotherapy."
    },
    {
      "ticker": "RGNX",
      "name": "Regenxbio",
      "development_stage": "platform",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.6B",
      "ir_url": "",
      "notes": "AAV gene therapy platform. Multiple programs."
    },
    {
      "ticker": "RLAY",
      "name": "Relay Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$1.2B",
      "ir_url": "",
      "notes": "Oncology - precision medicine. Lead: RLY-2608."
    },
    {
      "ticker": "RNA",
      "name": "Avidity Biosciences",
      "development_stage": "platform",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$3.0B",
      "ir_url": "",
      "notes": "Neuromuscular, Cardio. Lead: del-desiran (Ph3)."
    },
    {
      "ticker": "ROIV",
      "name": "Roivant Sciences",
      "development_stage": "commercial_stage",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$8.0B",
      "ir_url": "",
      "notes": "Diversified biotech. Multiple Vants."
    },
    {
      "ticker": "RVMD",
      "name": "Revolution Medicines",
      "development_stage": "commercial_stage",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$8.0B",
      "ir_url": "",
      "notes": "Oncology - RAS inhibitors. Lead: RMC-6236."
    },
    {
      "ticker": "RXRX",
      "name": "Recursion Pharmaceuticals",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$3.0B",
      "ir_url": "",
      "notes": "AI-driven drug discovery."
    },
    {
      "ticker": "RYTM",
      "name": "Rhythm Pharmaceuticals",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$3.5B",
      "ir_url": "",
      "notes": "Metabolic - Obesity. Key product: Imcivree."
    },
    {
      "ticker": "SAGE",
      "name": "Sage Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.8B",
      "ir_url": "",
      "notes": "Neuropsychiatry. Key product: Zurzuvae."
    },
    {
      "ticker": "SANA",
      "name": "Sana Biotechnology",
      "development_stage": "platform",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$1.2B",
      "ir_url": "",
      "notes": "Cell Engineering platform for hypoimmune cells."
    },
    {
      "ticker": "SGMO",
      "name": "Sangamo Therapeutics",
      "development_stage": "platform",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.2B",
      "ir_url": "",
      "notes": "Gene Therapy, Gene Editing."
    },
    {
      "ticker": "SMMT",
      "name": "Summit Therapeutics",
      "development_stage": "commercial_stage",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$15B",
      "ir_url": "",
      "notes": "Oncology - PD-1. Lead: ivonescimab."
    },
    {
      "ticker": "SRPT",
      "name": "Sarepta Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$8B",
      "ir_url": "",
      "notes": "Neuromuscular (DMD). Key product: Elevidys."
    },
    {
      "ticker": "SRRK",
      "name": "Scholar Rock Holding",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$1.5B",
      "ir_url": "",
      "notes": "Neuromuscular. Lead: apitegromab."
    },
    {
      "ticker": "STOK",
      "name": "Stoke Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.8B",
      "ir_url": "",
      "notes": "Rare - genetic epilepsies."
    },
    {
      "ticker": "SUPN",
      "name": "Supernus Pharmaceuticals",
      "development_stage": "commercial_stage",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$2.0B",
      "ir_url": "",
      "notes": "Neuropsychiatry. Key products: Qelbree, Trokendi XR."
    },
    {
      "ticker": "TALK",
      "name": "Talkspace",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.3B",
      "ir_url": "",
      "notes": "Mental Health - Digital therapeutics."
    },
    {
      "ticker": "TARS",
      "name": "Tarsus Pharmaceuticals",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$2.5B",
      "ir_url": "",
      "notes": "Ophthalmology. Key product: Xdemvy."
    },
    {
      "ticker": "TCRT",
      "name": "Alaunos Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.1B",
      "ir_url": "",
      "notes": "Oncology - TCR-T cell therapy."
    },
    {
      "ticker": "TERN",
      "name": "Terns Pharmaceuticals",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.5B",
      "ir_url": "",
      "notes": "Metabolic - MASH. Lead: TERN-501."
    },
    {
      "ticker": "TGTX",
      "name": "TG Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$4.5B",
      "ir_url": "",
      "notes": "I&I (MS). Key product: Briumvi."
    },
    {
      "ticker": "TVTX",
      "name": "Travere Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$3.0B",
      "ir_url": "",
      "notes": "Rare - Nephrology. Key product: Filspari."
    },
    {
      "ticker": "TWST",
      "name": "Twist Bioscience",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$2.5B",
      "ir_url": "",
      "notes": "Tools - DNA synthesis platform."
    },
    {
      "ticker": "UTHR",
      "name": "United Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$14B",
      "ir_url": "",
      "notes": "Rare - PAH. Key product: Tyvaso DPI."
    },
    {
      "ticker": "VCEL",
      "name": "Vericel",
      "development_stage": "commercial_stage",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$2.5B",
      "ir_url": "",
      "notes": "Regenerative. Key products: MACI, Epicel."
    },
    {
      "ticker": "VCYT",
      "name": "Veracyte",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$2.0B",
      "ir_url": "",
      "notes": "Dx - Oncology. Key products: Decipher, Afirma."
    },
    {
      "ticker": "VERA",
      "name": "Vera Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$3.0B",
      "ir_url": "",
      "notes": "Nephrology - IgAN. Lead: atacicept."
    },
    {
      "ticker": "VERV",
      "name": "Verve Therapeutics",
      "development_stage": "platform",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.5B",
      "ir_url": "",
      "notes": "Cardiovascular - gene editing."
    },
    {
      "ticker": "VIR",
      "name": "Vir Biotechnology",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$1.0B",
      "ir_url": "",
      "notes": "Infectious Disease. Key product: Xofluza partnership."
    },
    {
      "ticker": "VKTX",
      "name": "Viking Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$6.0B",
      "ir_url": "",
      "notes": "Metabolic - Obesity/MASH. Lead: VK2735."
    },
    {
      "ticker": "VRTX",
      "name": "Vertex Pharmaceuticals",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "ir_priority": "LOW",
      "has_data": false,
      "market_cap_mm": "$120B+",
      "ir_url": "",
      "notes": "Reference company for CF comparisons"
    },
    {
      "ticker": "VXRT",
      "name": "Vaxart",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.2B",
      "ir_url": "",
      "notes": "Oral vaccines platform."
    },
    {
      "ticker": "WVE",
      "name": "Wave Life Sciences",
      "development_stage": "platform",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$1.0B",
      "ir_url": "",
      "notes": "Genetic medicines - stereopure."
    },
    {
      "ticker": "XENE",
      "name": "Xenon Pharmaceuticals",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$3.0B",
      "ir_url": "",
      "notes": "Neuropsychiatry - Epilepsy. Lead: azetukalner."
    },
    {
      "ticker": "XNCR",
      "name": "Xencor",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$2.0B",
      "ir_url": "",
      "notes": "Oncology - bispecific antibodies."
    },
    {
      "ticker": "YMAB",
      "name": "Y-mAbs Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$0.5B",
      "ir_url": "",
      "notes": "Oncology - pediatric. Key product: Danyelza."
    },
    {
      "ticker": "ZLAB",
      "name": "Zai Lab",
      "development_stage": "commercial_stage",
      "modality": "mixed",
      "therapeutic_area": "mixed",
      "priority": "low",
      "has_data": false,
      "market_cap_mm": "$3.0B",
      "ir_url": "",
      "notes": "China-focused biotech."
    }
  ]
}